<DOC>
	<DOCNO>NCT02595450</DOCNO>
	<brief_summary>This non-interventional , open label , single arm , multicenter study assess safety efficacy erlotinib participant non-small cell lung cancer .</brief_summary>
	<brief_title>A Non-interventional Trial Erlotinib ( Tarceva ) Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>It physician 's decision prescribe erlotinib participant document treatment Participants must candidate receive erlotinib locally advance metastatic nonsmall cell lung cancer accord product label Participants exclude safety concern occur If participant compliant participant would wish stop erlotinib therapy</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>